MAPP

Metabolic Insights for APPs

Health EN ↓ 11 episodes

The Metabolic Advanced Practice Providers (MAPP) is the first association solely focused on Advanced Practice Providers (APPs) working with metabolic conditions. MAPP provides a unique opportunity for nurse practitioners and physician assistants to join under one membership to work towards a common goal of excellence in metabolic medicine. MAPP recognizes the gaps in the standards of education and training of advanced practice providers who choose to work with metabolic conditions. Our goal is to create a home for metabolic APPs and offer educational resources to fill in these gaps by providin...

Author

MAPP

Episodes

FAQ: Statins & MASH: How Manageable Is The Interaction? 17.03.2026 3:01

Thank you to Madrigal for sponsoring this FAQ Video Module. In this episode, Tammy Harper, NP-C, a transplant hepatology nurse practitioner at Keck Medicine of USC, shares real-world insights on managing statin therapy in patients with MASH and MASLD. Drawing from extensive experience in internal medicine and liver transplantation, she discusses when statins can be safely continued in cirrhosis, w...

Medication Review: Mechanism of Action: The First Liver-Directed Thyroid Hormone Agonist 17.03.2026 2:52

Thank you to Madrigal for sponsoring this Medication Review Video Module. In this video, Jessica Bartholomew, MSN, APRN, FNP-C, reviews the mechanism of action of resmetirom, the first FDA-approved liver-directed therapy for non-cirrhotic metabolic dysfunction–associated steatohepatitis (MASH) in patients with stage F2–F3 fibrosis. The discussion explains how selective activation of thyroid hormon...

FAQ: How Do You Decide What Testing To Do When Screening Patients For Hypercortisolism? 17.03.2026 5:26

Thank you to Corcept for sponsoring this FAQ Video Module. In this educational endocrinology update, Amy Burmesh, PA-C, from the Medical College of Wisconsin shares a practical, step-by-step approach to screening for hypercortisolism and Cushing syndrome in clinical practice. She reviews the three primary screening tests for cortisol excess: the 24-hour urine free cortisol, late-night salivary cor...

Medication Review: Prescribing in Practice: Safety, Monitoring, and Drug-Drug Interactions For Resmetirom 17.03.2026 3:32

Thank you to Madrigal for sponsoring this Medication Review Video Module. In this educational video, Andrew Garza, MPAS, PA-C, provides a comprehensive clinical overview of safety monitoring, adverse events, and drug–drug interactions associated with Resmetirom, the first FDA-approved therapy for metabolic dysfunction–associated steatohepatitis (MASH) with F2–F3 fibrosis. Drawing from both clinica...

Podcast: Fibrosis—Not Steatosis—Is the True Prognostic Driver in MASLD and MASH 17.03.2026 16:27

Thank you to Madrigal for sponsoring this podcast episode. This educational discussion explores why fibrosis—not steatosis—is the key prognostic driver in metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Physician assistants Kelsey Gaid, PA-C from the University of Utah Health and Andrew Garza, MPAS, PA-C review how fibro...

FAQ: Is Hypercortisolism a Common Condition? 28.01.2026 4:47

Thank you to Corcept Therapeutics for sponsoring this FAQ Video Module. This FAQ video features endocrinology David Doriguzzi, PA-C, discussing emerging data showing that cortisol excess frequently goes unrecognized in patients with insulin resistance, refractory hypertension, and unexplained weight gain. Drawing on recent clinical trial evidence, he explains why nearly one in four patients with t...

FAQ: How Do You Use the Dexamethasone SuppressionTest? 28.01.2026 5:32

Thank you to Corcept Therapeutics for sponsoring this FAQ Video Module. In this FAQ video, endocrinology David Doriguzzi, PA-C, breaks down how to screen for hypercortisolism using the 1 mg dexamethasone suppression test (DST). He explains the physiology behind cortisol suppression, how to correctly interpret post-dexamethasone cortisol levels, and why results that appear “low” on lab reports may...

FAQ: Who Should Clinicians Be Screening For Hypercortisolism? 28.01.2026 3:01

Thank you to Corcept Therapeutics for sponsoring this FAQ Video Module. In this FAQ video, Amy Burmesch, PA-C, discusses which patients with type 2 diabetes should be screened for hypercortisolism. She outlines key high-risk subgroups, including younger patients without a family history of diabetes, individuals with difficult-to-control diabetes despite multiple therapies, and patients with low bo...

FAQ: I Have a Patient Who Is Uncontrolled — What Do I Do Now? 28.01.2026 3:01

Thank you to Corcept Therapeutics for sponsoring this FAQ Video Module. In this FAQ video, Benny Lopez, BC-ADM, DMSc, PA-C, discusses what to do when patients with type 2 diabetes remain uncontrolled despite following ADA guidelines. He explains why clinicians should look beyond glycemic control and consider underlying causes such as hypercortisolism. The video reviews when to screen uncontrolled...

Podcast: Hypercortisolism in 2026: Looking Past What You Thought You Knew 28.01.2026 19:24

Thank you to Corcept Therapeutics for sponsoring this podcast episode. In this episode, Natalie Bellini, CNP, and Davida Kruger, MSN, APN-BC, BC-ADM, explore why elevated cortisol is an underrecognized driver of difficult-to-control type 2 diabetes and hypertension. This episode breaks down how hypercortisolism differs from classic Cushing syndrome, reviews data showing a high prevalence in patien...

FAQ: GLP-1 Alone or Add Resmetirom? Managing MASH When Diabetes Therapy Is Already Onboard 28.01.2026 3:21

Thank you to Madrigal for sponsoring this FAQ Video Module. In this FAQ video, Kelsey Gaid, PA-C, from the University of Utah Health reviews the role of combining GLP-1 receptor agonists with resmetirom for the treatment of MASH with stage 2–3 fibrosis. This video explains why lifestyle changes and GLP-1 therapy alone may be insufficient for fibrosis regression, highlights data from the MAESTRO-NA...